Deans' stroke musings: Prior Cannabis Use Is Associated with better Outcome after Intracerebral Hemorrhage

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, February 20, 2016

Prior Cannabis Use Is Associated with better Outcome after Intracerebral Hemorrhage

Well, see what your doctor has to say about this pretreatment for stroke with cannabis. Although this is correlation not cause. Tweak your doctor anyway about this. Or is the better result because these were young patients? Doesn't anyone in stroke understand cause and effect?
http://www.karger.com/Article/Abstract/443532
Di Napoli M.^{a, b} · Zha A.M.^c · Godoy D.A.^{d, e} · Masotti L.^f · Schreuder F.H.B.M.^g · Popa-Wagner A.^{h, i} · Behrouz R.^j · from the MNEMONICH Registry
^aNeurological Service, San Camillo de' Lellis General Hospital, Rieti, ^bNeurological Section, SMDN - Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, Sulmona, L'Aquila, Italy; ^cDepartment of Neurology, Ohio State University College of Medicine, Columbus, Ohio, USA; ^dThe Neurointensive Care Unit, Sanatorio Pasteur and ^eIntensive Care Unit, Hospital Interzonal de Agudos ‘San Juan Bautista', Catamarca, Argentina; ^fDepartment of Internal Medicine, Santa Maria Nuova Hospital, Florence, Italy; ^gDepartment of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands; ^hDepartment of Psychiatry, Rostock University Medical School, Rostock, Germany; ⁱUniversity of Medicine and Pharmacy, Craiova, Romania; ^jDepartment of Neurology, School of Medicine, University of Texas Health Science Center San Antonio, San Antonio, Tex., USA

Abstract

Objective: Recent evidence suggests that a potential harmful relationship exists between cannabis use and ischemic stroke(not proven). The purpose of this study was to determine the implications of cannabis use in intracerebral hemorrhage (ICH) patients.
Methods: An analysis of an international, multicenter, observational database of consecutive patients with spontaneous ICH was conducted. We extracted the following characteristics on presentation: demographics, risk factors, antiplatelet or anticoagulant use, Glasgow Coma Scale, ICH score, neuroimaging parameters, and urine toxicology screen (UTS) results. Modified Rankin Scale (mRS) score was utilized for determination of outcome at discharge. Adjusted logistic ordinal regression was used as shift analysis to assess the impact of cannabis use on mRS score at discharge. The adjusted common OR measured the likelihood that cannabis use would lead to lower mRS scores.
Results: Within a cohort of 725 spontaneous ICH patients, UTS was positive for cannabinoids in 8.6%. Cannabinoids-positive (CB⁺) patients were more frequently Caucasian (p < 0.001), younger (p < 0.001), and had lower median ICH scores on admission (p = 0.017) than those who were cannabinoids-negative. CB⁺ patients also showed a shift toward better outcome in the distribution of mRS categories, with an adjusted common OR of 0.544 (95% CI 0.330-0.895, p = 0.017). Conclusion: In this multinational cohort, cannabis use was discovered in nearly 10% of patients with spontaneous ICH. Although there was no relationship between cannabis use and specific ICH characteristics, CB⁺ patients had milder ICH presentation and less disability at discharge.